Tag: ARNA

ATRN, ARNA & Today’s Extended Watchlist

 

Atrinsic, Inc. ATRN

ATRN is a stock we have been covering for quite some time. Some of you may recall the huge run exhibited by the stock earlier this year. Following our alert in January, the stock was trading as low as .012, only to hit a high of .3599 by February for one of our biggest gains all year, totaling 2899% .

As for the present situation, the stock has not been this low since January, and while we do not expect a run of the magnitude we saw before, even a run to the 50DMA of .07, from this level would yield a gain of 100%

We’d like to see the stock hold its key level of support .035, and are looking for a break past .05 (20DMA), which is the first main area of resistance.

____

Arena Pharmaceuticals, Inc. ARNA

ARNA continues to pile up the gains since we began mentioning it back on May 11th , having risen a total of 53% since that time.

We said that the time leading up to the company’s prosposed FDA approval date of 06/27 was going to be interesting, and we were correct. The stock continues to run as we approach zero hour, and we are certainly excited to see the results, and how the stock is affected at that time.

____

Extended Watchlist:

XG (Coming off lows), WEST, ICPA, THWI,

IBIO, ARNA, & Today’s Extended Watchlist

iBio, Inc. IBIO

We’ve been quietly watching IBIO for quite some time. This AMEX stock has been on a consistant downtrend for the past couple of months, and is reaching the point where we felt it was time to begin sniffing for a bottom.

As you can see from the chart below, IBIO has the look of a stock that could be in for quite a recovering run once that ultimate bottom is reached. Shares from this price level could really turn out to be a bargain in the long run.

_____

Arena Pharmaceuticals, Inc. ARNA

ARNA hit a high of 8.65 on Wednesday.  That’s a 57% gain from the stock’s low (5.50) following our initial alert. It appears that many investors are, like us, highly anticpating the possibility of ARNA’s FDA Approval.

We’ve already seen sizable gains from ARNA, and certainly would like to keep the stock on our radars for the forseeable future. We will, of course, keep you updated as to the situation.

____

We’d like to congratulate any traders who managed to trade RGIN successfully yesterday, as it was not for the faint of heart. The stock opened at .285 yesterday, and hit a high of .44 before falling into the close at .20. Savvy traders could still have made an intraday gain of 54% early on, and if anyone caught the afternoon bounce from .151 to .249 that came following the high of day, an additional 62% gain was possible.

____

Extended Watchlist:
JASO, VPER, THWI, OMVE

YIPI, ARNA & Today’s Extended Watchlist

YIPI recently caught our attention, as a stock that has been on a steady incline for months now. Yesterday’s activity was exciting, and despite the Dow being down over 100 points, YIPI managed a nearly 60% gain.

Any stock that is doing this well during a relatively turbulent time is certainly worth a second look.

The company also had some news out yesterday:

Yippy, Inc. (YIPI) and MuseGlobal to Merge, Offering Unified Access to a Data Cloud of Curated Content

http://www.yippy.com

____

Arena Pharmaceuticals, Inc. ARNA

This stock has appeared on our newsletters before. On May 11th, we stated that “we want to watch this play carefully heading into the month of June, being the target month for FDA approval, as we believe that there could be trading opportunities in the meantime”

We turned out to be correct. In the days following our alert, the stock was trading as low as 5.50, and yesterday reached a high of 7.23, for a 31% gain. Should the company indeed receive the FDA approval it seeks, that 31% could be just a drop in bucket of some much larger gains.

We will keep our eyes peeled for any additional press coming over the wires. In the meantime here’s a link to this morning’s announcement:

Arena and VIVUS Race to Be the First in the Lucrative Anti-Obesity Drug Market

____
Extended Watchlist:

EEGC, CLNO